Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients
Key result
CYP2C19 poor metabolizer status was associated with a significantly higher risk of myocardial infarction and death in elderly patients undergoing PCI (HR 2.43; 95% CI 1.12-5.24; p=0.024).
Why the study?
Elderly PCI patients face higher ischemic and bleeding risks, but few studies have reported how genetic variants affect their clinical outcomes.
Do CYP2C19 and P2Y12 G52T genetic variants predict clinical outcomes in elderly patients (≥75 years) undergoing PCI?
Population
811 elderly patients (≥75 years of age) treated with PCI
Comparison
CYP2C19 and P2Y12 receptor gene G52T polymorphisms
Design
Prospective multicenter registry study
Authors
Discussion
Loading...
Member takes
Implication
May identify higher ischemic risk in elderly CYP2C19 poor metabolizers post-PCI; leaves open whether genotyping improves outcomes.
Study Design
Type
Cohort (n=811)
Multicenter
Yes
Structured PICO
Do CYP2C19 and P2Y12 G52T genetic variants predict clinical outcomes in elderly patients (≥75 years) undergoing PCI?
P
Population
811 elderly patients (≥75 years of age) treated with percutaneous coronary intervention from a prospective multicenter registry.
E
Exposure
Presence of CYP2C19 poor metabolizer phenotype or P2Y12 receptor gene G52T TT polymorphism
C
Comparator
Patients without these specific genetic variants (non-poor metabolizers of CYP2C19 and non-TT groups of P2Y12 G52T)
O
Outcome
Composite of myocardial infarction and deathcomposite
Main Result
Hazard Ratio: 2.43 (95% CI 1.12–5.24)
p-value: p=0.024
In elderly patients undergoing PCI, CYP2C19 poor metabolizer status predicts ischemic events and death, while the P2Y12 G52T TT genotype predicts major bleeding.
Cite This Study
Cha et al. (2021) conducted a cohort in percutaneous coronary intervention (n=811). CYP2C19 poor metabolizer status and P2Y12 G52T TT genotype vs. Other genotypes was evaluated on composite of myocardial infarction and death (HR 2.43, 95% CI 1.12-5.24, p=0.024). CYP2C19 poor metabolizer status was associated with a significantly higher risk of myocardial infarction and death in elderly patients undergoing PCI (HR 2.43; 95% CI 1.12-5.24; p=0.024).